Company intelligence / Profile preview
Virogenics, Inc.
San Diego, California, United States
- Ownership
- Private
- Employees
- ~4
- Development stage
- Other
01
Overview
Virogenics has one drug (CMS121) in Phase 1 clinical trials for Alzheimer's Disease as of April 2025. The company is developing innovative viral vectors for potential treatment of HIV and Hemophilia, as well as immunotherapies for Alzheimer's Disease and other CNS disorders.
- Therapeutic areas
- HematologyNeurologyInfectious Diseases
- Modalities
- Gene therapiesstem cell technologyviral vectorsimmunotherapies
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Virogenics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Virogenics, Inc..